|Positive IHC detected in||human breast cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive FC detected in||A431 cells|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
11594-1-AP targets ACP5 in IHC, IF, FC, ELISA applications and shows reactivity with human samples.
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||ACP5 fusion protein Ag2065|
|Full Name||acid phosphatase 5, tartrate resistant|
|Calculated molecular weight||325 aa, 37 kDa|
|GenBank accession number||BC025414|
|Gene ID (NCBI)||54|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
ACP5(acid phosphatase 5, tartrate resistant) is also named as TRAP, TrATPase and belongs to the metallophosphoesterase superfamily. It is an iron-containing glycoprotein with a molecular mass of approximately 34 kD. ACP5 is a histochemical marker of the osteoclast. It is also characteristic of monohistiocytes, particularly alveolar macrophages, and is associated with diverse pathological conditions, including hairy cell leukemia and AIDS encephalopathy.(PMID:10639488).
Secreted Klotho Attenuates Inflammation-Associated Aortic Valve Fibrosis in Senescence-Accelerated Mice P1.
Med Sci Monit
Fluid Shear Stress Suppresses Osteoclast Differentiation in RAW264.7 Cells through Extracellular Signal-Regulated Kinase 5 (ERK5) Signaling Pathway.
Exp Ther Med
4-Hexylresorcinol inhibits osteoclastogenesis by suppressing the NF-κB signaling pathway and reverses bone loss in ovariectomized mice.
J Bone Miner Metab
miR-142-5p promotes the osteoclast differentiation of bone marrow-derived macrophages via PTEN/PI3K/AKT/FoxO1 pathway.
Prognostic Significance of ACP5 in Human Gastric Cancer.
J Cell Biochem
(2R,3R)Dihydromyricetin inhibits osteoclastogenesis and bone loss through scavenging LPS-induced oxidative stress and NF-κB and MAPKs pathways activating.